Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Kalivir Immunotherapeutics, Inc. (United States)
Homepage:
kalivir.com
Alternate name:
Kalivir Immunotherapeutics
ROR:
009yn9w19
OpenAlex ID:
I4405253087
An oncolytic virus–delivered TGFβ inhibitor overcomes the immunosuppressive tumor microenvironment
2023
·
Kristin DePeaux
, Dayana B. Rivadeneira
, et al.
·
The Journal of Experimental Medicine
·
61
PDF
An IRF2-Expressing Oncolytic Virus Changes the Susceptibility of Tumor Cells to Antitumor T Cells and Promotes Tumor Clearance
2024
·
Lulu Shao
, Rashmi Srivastava
, et al.
·
Cancer Immunology Research
·
5
PDF
894 A novel oncolytic immunotherapy, VET3-TGI, overcomes TGFB1 mediated immunosuppression, augments type-1 immune response, and displays potent therapeutic activity in multiple mouse tumor models
2022
·
Ravikumar Muthuswamy
, Steve Thorne
, et al.
·
Journal for ImmunoTherapy of Cancer
·
2
PDF
Abstract 6789: The oncolytic virus VET3-TGI both blocks TGF-beta signaling and activates type 2 IFN responses, resulting in potent therapeutic responses in multiple mouse models
2023
·
Ravikumar Muthuswamy
, Steve Thorne
·
Cancer Research
·
1
572 STEALTH-001: a phase 1 study of VET3-TGI, an oncolytic vaccinia virus encoding TGFb inhibitor and IL-12, for the treatment of advanced solid tumors
2026
·
Yana G Najjar
, Siqing Fu
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Intravenously deliverable oncolytic virus VET3-TGI favorably alters the tumor microenvironment
2026
·
Ming Zhang
, Katy Barrett
, et al.
·
Journal for ImmunoTherapy of Cancer
The oncolytic viral immunotherapy ASP1012 optimizes memory T cell responses after systemic delivery
2026
·
Ravikumar Muthuswamy
, Carly Carter
, et al.
·
Molecular Therapy
Abstract 484: Mechanisms of synergy between TGF-beta inhibitor and IL12 expression from the systemically deliverable clinical oncolytic immunotherapy VET3-TGI
2025
·
Steve Thorne
·
Cancer Research
1394 Novel oncolytic viral immunotherapy VET3-TGI displays enhanced systemic delivery and inhibits TGFb-signaling while augmenting type-1 immune response in the tumor
2023
·
Steve Thorne
·
Journal for ImmunoTherapy of Cancer
PDF
743 Resistance to oncolytic vaccinia can be reversed by targeting regulatory T cells with vaccinia-directed delivery of a TGFβ inhibitor
2021
·
Kristin DePeaux
, Dayana Rivadeneira
, et al.
·
Journal for ImmunoTherapy of Cancer
PDF
Show more works
View as search
Works count:
10
Citation count:
69
Year
Topic
Type